CD274 and non-small cell lung carcinoma: A meta-analysis confirmed that the superiority of ICIs was over docetaxel in pretreated non-small-cell lung cancer patients and indicated a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors [20].